Pulmocide

Focus: Pulmocide is a UK-based biotechnology company specializing in inhaled anti-infectives targeting infectious diseases and respiratory conditions. The company is pre-revenue and early-stage with a focused pipeline in respiratory fungal and viral infections.

Infectious Diseases Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Pulmocide

AI assessmentNot Hiring

No open roles listed right now. Follow Pulmocide to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Nasal and Bronchial Sampling

Bronchiolitis

N/A

Clinical Trials (1)

NCT03062917Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis

N/A

Help build intelligence for Pulmocide

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Rare disease focus in aspergillosis and RSV with Phase 3 data (PC945 refractory IPA) de-risking the platform
Highly specialized inhaled delivery platform offers deep technical expertise not common across pharma
Early-stage opportunity to shape company trajectory with exposure to preclinical-to-Phase 3 development

Watch Out For

Zero current job openings signals potential hiring freeze or very tight headcount during early funding stage
Missing critical data (funding, employee count, founding date) indicates lack of public visibility and possible capital constraints
Pre-revenue status with no approved products means job security depends entirely on continuous funding and trial success

Generated by Claude from Pulmocide's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PC945 - single doses

Aspergillosis

Phase 1

Clinical Trials (1)

NCT02715570A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

Phase 1

PC786 - Single doses

Respiratory Syncytial Virus (RSV)

Phase 1

Clinical Trials (1)

NCT03236233A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786

Phase 1

PC786

Respiratory Syncytial Virus Infections

Phase 1/2

Clinical Trials (1)

NCT03382431A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study

Phase 1/2

Opelconazole

Pulmonary Aspergillosis

Phase 2

Clinical Trials (1)

NCT05037851A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

Phase 2

PC945

Aspergillosis

Phase 2

Clinical Trials (1)

NCT03870841The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis

Phase 2

PC945

Aspergillosis

Phase 2

Clinical Trials (1)

NCT03905447The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.

Phase 2

PC786

Respiratory Syncytial Virus Infections

Phase 2

Clinical Trials (1)

NCT03715023Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients

Phase 2

PC945

Asthma

Phase 2

Clinical Trials (1)

NCT03745196The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases

Phase 2

PC945

Refractory IPA

Phase 3

Clinical Trials (1)

NCT05238116Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

Phase 3